Prostate cancer vaccine, approved

The Food and Drug Administration has finally approved what has been in the works since 2006–a drug that actually prevents it from spreading.

The drug, named Provenge, was made by the Seattle-based company Dendreon.

Provenge is for patients who have advanced cases of prostate cancer. The drug will be used to prevent the further spread of the disease in the person’s body. Provenge has been said to have no serious side effects like the ones associated with chemotherapy, hormone, and radiation therapy.

The approval of Provenge can be considered as a milestone in cancer research and can usher in a new era of treatment for caner.

Patients will have a new treatment option. Also, the fact that the drug can be used in advanced stages can be deemed hopeful for patients who are in the early stages of prostate cancer. This means that the drug has the possibility of providing a more successful treatment for patients in the early stages.

Healthday reports: “Provenge is a therapeutic (not preventative) vaccine that is made from the patient’s own white blood cells. Once removed from the patient, the cells are treated with the drug and placed back into the patient. These treated cells then cause an immune response, which in turn kills cancer cells, while leaving normal cells unharmed.”

The drug Provenge is given to a prostate cancer patient intravenously.